Sagefield Capital’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Sagefield Capital’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7,000	Closed	-$527K	–	169
2022 Q2	$527K	Buy	+7,000	New	+$311K	0.24%	67

Sagefield Capital's TPTX Position: Q3 2022 in Review

Sagefield Capital sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 7,000 shares — an estimated $527K sold.

Sagefield Capital first reported a position in TPTX in Q2 2022 and held it in 1 quarter. The position peaked at $527K in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Sagefield Capital reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Sagefield Capital sold 7,000 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $527K.
Sagefield Capital first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
Sagefield Capital's Turning Point Therapeutics, Inc. Common Stock position peaked at $527K in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Sagefield Capital's 13F filing for Q3 2022, filed 14 Nov 2022.